Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 19/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488426 | 1.00 | KMT2A (0.52) | KMT2ADPP4 | |
| SCHEMBL13936193 | 0.90 | DPP4 (0.60) | KMT2ADPP4 | |
| SCHEMBL13936181 | 0.90 | DPP4 (0.46) | KMT2ADPP4 | |
| SCHEMBL13936189 | 0.90 | DPP4 (0.43) | KMT2ADPP4 | |
| SCHEMBL13936234 | 0.89 | DPP4 (0.49) | KMT2ADPP4 | |
| SCHEMBL13936187 | 0.88 | KMT2A (0.53) | KMT2ADPP4 | |
| SCHEMBL4483972 | 0.88 | DPP4 (0.46) | KMT2ADPP4 | |
| SCHEMBL4483980 | 0.88 | DPP4 (0.46) | KMT2ADPP4 | |
| SCHEMBL8272356 | 0.87 | DPP4 (0.56) | KMT2ADPP4 | |
| SCHEMBL4475040 | 0.87 | KMT2A (0.52) | KMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797093-B1 | NOVEL 3-METHYL-7-BUTINYL-XANTHINES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2012-05-30 | — | — | EP | claimed |
| US-7495002-B2 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-24 | — | — | US | claimed |
| US-20060079541-A1 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-13 | — | — | US | claimed |
| US-7495002-B2 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-24 | — | — | US | disclosed |
| US-20060079541-A1 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079541-A1 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | KMT2A 2557/4885DPP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.